Shares of Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) traded up 5.3% during trading on Monday . The stock traded as high as $7.65 and last traded at $7.65. 1,436 shares changed hands during mid-day trading, a decline of 55% from the average session volume of 3,181 shares. The stock had previously closed at $7.2640.
Clinuvel Pharmaceuticals Stock Up 1.0%
The firm has a 50 day moving average of $7.55 and a 200 day moving average of $7.39.
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Read More
- Five stocks we like better than Clinuvel Pharmaceuticals
- Investing In Preferred Stock vs. Common Stock
- 3 Stocks Poised to Benefit From Google’s AI Breakthough
- How to invest in marijuana stocks in 7 steps
- Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026
- How Technical Indicators Can Help You Find Oversold Stocks
- 3 Stocks You’ll Wish You Bought Before 2026
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
